Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur Urol. 2015 Feb;67(2):353-4. doi: 10.1016/j.eururo.2014.10.012. Epub 2014 Oct 27.

Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.

Author information

  • 1Rutgers Cancer Institute of New Jersey; Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. Electronic address: mark.stein@rutgers.edu.
  • 2Rutgers Cancer Institute of New Jersey; Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
  • 3Rutgers Cancer Institute of New Jersey; Department of Pathology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
  • 4Rutgers Cancer Institute of New Jersey; Section of Urologic Oncology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
  • 5Foundation Medicine, Cambridge, Massachusetts, USA.
PMID:
25457019
DOI:
10.1016/j.eururo.2014.10.012
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center